DXC006 / Hangzhou DAC Biotech - LARVOL DELTA

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies (AACR 2024) - "Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal nonoverlapping epitopes. mAbs 2016; 799-810."

PK/PD data • Preclinical • CNS Tumor • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Neuroblastoma • Oncology • Small Cell Lung Cancer • Solid Tumor • NCAM1

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd.

Metastases • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor